
    
      The primary objective of this study is to prospectively generate clinical data on
      device-related adverse events in a post-market setting using ECHELON ENDOPATH Staple Line
      Reinforcement per its instructions for use. There will be no blinding in this study. An
      interim analysis is planned for sample-size re-estimation.
    
  